{"id":3547,"date":"2024-06-05T15:17:12","date_gmt":"2024-06-05T12:17:12","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3547"},"modified":"2024-06-05T15:20:10","modified_gmt":"2024-06-05T12:20:10","slug":"novartis-kurtkoy-uretim-tesisi-20-yilini-kutluyor","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3547","title":{"rendered":"Novartis Kurtk\u00f6y \u00dcretim Tesisi 20. Y\u0131l\u0131n\u0131 Kutluyor"},"content":{"rendered":"\n

Novartis Kurtk\u00f6y \u00dcretim Tesisi <\/strong>2004 y\u0131l\u0131ndan bu yana faaliyet g\u00f6steriyor. Tesistee kanser, hipertansiyon, kolesterol, s\u0131tma ve a\u011fr\u0131 gibi hastal\u0131klar\u0131n tedavisinde kullan\u0131lan bir\u00e7ok Novartis ilac\u0131n\u0131n kat\u0131 oral formlar\u0131 \u00fcretiliyor. S\u00fcrekli iyile\u015ftirme ve yenilik sa\u011flamak i\u00e7in her y\u0131l \u00f6nemli oranda yat\u0131r\u0131m yapan Novartis Kurtk\u00f6y \u00dcretim Tesisi hem T\u00fcrkiye ekonomisine hem de toplum sa\u011fl\u0131\u011f\u0131na katk\u0131da bulunuyor.<\/em><\/strong> Tesisin 20. y\u0131l kutlamas\u0131 \u00e7er\u00e7evesinde d\u00fczenlenen etkinlikte Novartis T\u00fcrkiye \u00dclke Ba\u015fkan\u0131 Natacha Theytaz Novartis’in T\u00fcrkiye’deki yat\u0131r\u0131mlar\u0131 ve hedeflerine y\u00f6nelik payla\u015f\u0131mlarda bulundu.<\/em>
<\/strong><\/p>\n\n\n\n

\u00dcretim faaliyetlerine A\u011fustos 2004’te ba\u015flayan Novartis Kurtk\u00f6y \u00dcretim Tesisi kuruldu\u011fu g\u00fcnden bu yana b\u00fcy\u00fcyerek Novartis k\u00fcresel \u00fcretim a\u011f\u0131n\u0131n \u00f6nemli bir par\u00e7as\u0131 haline geldi. 150 ki\u015fi ile ba\u015flayan yolculu\u011funa bug\u00fcn 410 \u00e7al\u0131\u015fan\u0131yla devam eden fabrika, Novartis b\u00fcnyesinde hem yerel hem de ihracat pazarlar\u0131 i\u00e7in oral kat\u0131 form (tablet, kaps\u00fcl, film tablet, efervesan) \u00fcretiminde uzmanla\u015fm\u0131\u015f \u00f6nemli bir ila\u00e7 \u00fcretim tesisi olarak \u00f6ne \u00e7\u0131k\u0131yor. 52 bin m\u00b2’si yerle\u015fim alan\u0131 olmak \u00fczere toplam 110 bin m\u00b2’lik bir alana yay\u0131lan tesis, Fabrika Direkt\u00f6r\u00fc Filiz G\u00fcndo\u011fmu\u015f y\u00f6netiminde y\u0131ll\u0131k 130 milyon kutu gibi etkileyici bir \u00fcretim kapasitesine sahipken, T\u00fcrkiye i\u00e7in yapt\u0131\u011f\u0131 \u00fcretimlerin yan\u0131 s\u0131ra d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndaki 120 \u00fclkeye de ihracat yap\u0131yor.

Tesisin 20. y\u0131l kutlamas\u0131 \u00e7er\u00e7evesinde d\u00fczenlenen etkinli\u011fe Novartis T\u00fcrkiye \u00dclke Ba\u015fkan\u0131 Natacha Theytaz ve Novartis K\u00fcresel Sa\u011fl\u0131k ve S\u00fcrd\u00fcr\u00fclebilirlik Ba\u015fkan\u0131 Lutz Hegemann kat\u0131larak, de\u011ferlendirmelerde bulundu. Etkinli\u011fe \u0130svi\u00e7re’nin \u0130stanbul Ba\u015fkonsoloslu\u011fu’ndan bir heyetin kat\u0131l\u0131m\u0131 da ger\u00e7ekle\u015fti.

Novartis Kurtk\u00f6y tesisinin 20. y\u0131l d\u00f6n\u00fcm\u00fcn\u00fcn kutlama etkinli\u011finde konu\u015fan Novartis \u00dclke Ba\u015fkan\u0131 Natacha Theytaz, \u015firketin T\u00fcrkiye’deki k\u00f6kl\u00fc varl\u0131\u011f\u0131n\u0131 ve \u00fclkeye olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 vurgulayarak \u201cNovartis, T\u00fcrkiye’de 1955 y\u0131l\u0131ndan bu yana faaliyet g\u00f6steriyor. \u00dcretimde, ara\u015ft\u0131rma & geli\u015ftirme alan\u0131nda, sahada ve genel merkezde bine yak\u0131n \u00e7al\u0131\u015fma arkada\u015f\u0131m\u0131zdan olu\u015fan \u00f6zverili ekibimiz, sa\u011fl\u0131k hizmetlerine katk\u0131da bulunmak i\u00e7in tutkuyla \u00e7al\u0131\u015f\u0131yor. Yirmi y\u0131ld\u0131r faaliyet g\u00f6steren ve halihaz\u0131rda 30’dan fazla fabrikadan olu\u015fan k\u00fcresel a\u011f\u0131m\u0131z\u0131n ayr\u0131lmaz bir par\u00e7as\u0131 olan Kurtk\u00f6y fabrikam\u0131zda, kronik hastal\u0131klardaki \u00f6nemli tedaviler de dahil olmak \u00fczere hayat de\u011fi\u015ftiren ila\u00e7lar \u00fcretiyoruz. Sadece 2023 y\u0131l\u0131nda 80 farkl\u0131 \u00fcr\u00fcn \u00fcreterek 107 milyon \u00fcnite gibi etkileyici bir rakama ula\u015ft\u0131k. Bunun yan\u0131 s\u0131ra  2023 y\u0131l\u0131nda 53 farkl\u0131 tedavimiz T\u00fcrkiye’de 6,5 milyon hastaya ula\u015ft\u0131. Bu ba\u015far\u0131lar\u0131, Novartis olarak sa\u011fl\u0131k hizmetlerini geli\u015ftirmeye, hastalar\u0131n ya\u015famlar\u0131n\u0131 iyile\u015ftirmeye ve payda\u015flar\u0131m\u0131zla ortakl\u0131klar ger\u00e7ekle\u015ftirerek T\u00fcrkiye’nin b\u00fcy\u00fcmesini ve geli\u015fmesini desteklemeye olan sars\u0131lmaz ba\u011fl\u0131l\u0131\u011f\u0131m\u0131z\u0131n bir g\u00f6stergesi olarak g\u00f6r\u00fcyoruz\u201d dedi.

Lutz Hegemann ise \u201cGlobal Sa\u011fl\u0131k ve S\u00fcrd\u00fcr\u00fclebilirlik birimi olarak amac\u0131m\u0131z, nerede ya\u015farsa ya\u015fas\u0131n veya sosyo-ekonomik durumu ne olursa olsun herkesin yenilik\u00e7i tedavilerimizden faydalanabilmesini sa\u011flamak ve s\u00fcrd\u00fcr\u00fclebilir bir i\u015fletme olarak sosyal etkimizi en \u00fcst d\u00fczeye \u00e7\u0131karmak. Bu tutkumuzu ger\u00e7ekle\u015ftirmek i\u00e7in, s\u0131tma gibi \u00e7\u00f6z\u00fclmemi\u015f k\u00fcresel sa\u011fl\u0131k sorunlar\u0131n\u0131n \u00fcstesinden gelmek amac\u0131yla k\u00fcresel sa\u011fl\u0131k ve i\u015f yeteneklerini birle\u015ftiriyoruz” diye konu\u015ftu.<\/p>\n\n\n\n


Hegemann, Kurtk\u00f6y tesisinin Novartis Global Sa\u011fl\u0131k \u00e7al\u0131\u015fmalar\u0131ndaki \u00f6nemini vurgulayarak \u015funlar\u0131 ekledi: \u201c2015 y\u0131l\u0131ndan bu yana Kurtk\u00f6y tesisimizde g\u00f6rev yapan arkada\u015flar\u0131m\u0131z, her y\u0131l d\u00fcnya genelinde 600.000 ki\u015finin hayat\u0131n\u0131 kaybetti\u011fi s\u0131tma hastal\u0131\u011f\u0131na kar\u015f\u0131 milyonlarca doz tedavinin \u00fcretilmesini sa\u011flad\u0131lar. Buradaki meslekta\u015flar\u0131m\u0131z\u0131n \u00f6zverisi ve s\u0131k\u0131 \u00e7al\u0131\u015fmalar\u0131, d\u00fcnyan\u0131n acil sa\u011fl\u0131k sorunlar\u0131ndan birinin ele al\u0131nmas\u0131nda hayati bir rol oynuyor. Novartis Kurtk\u00f6y’\u00fcn s\u0131tma ile m\u00fccadeleye yapt\u0131\u011f\u0131 katk\u0131 paha bi\u00e7ilemez.\u201d

\u00c7evresel ayak izlerini azaltman\u0131n Novartis’in stratejisinin \u00f6nemli par\u00e7as\u0131 oldu\u011funun alt\u0131n\u0131 \u00e7izen Hegemann, 5 Haziran’\u0131n D\u00fcnya \u00c7evre G\u00fcn\u00fc oldu\u011funu da hat\u0131rlatarak \u015firketin \u00e7evresel s\u00fcrd\u00fcr\u00fclebilirlik konusundaki taahh\u00fctlerini de payla\u015ft\u0131: \u201c\u0130klim, at\u0131k ve su \u00fczerindeki etkilerimizi en aza indirmek i\u00e7in iddial\u0131 hedefler belirledik. 2030 y\u0131l\u0131na kadar de\u011fer zincirimizde karbon n\u00f6trl\u00fc\u011fe ula\u015fmay\u0131 ve 2040 y\u0131l\u0131na kadar net s\u0131f\u0131r karbon emisyonu sa\u011flamay\u0131 ama\u00e7l\u0131yoruz. Ayr\u0131ca, 2030 y\u0131l\u0131na kadar operasyonlar\u0131m\u0131zda su ve plastik a\u00e7\u0131s\u0131ndan n\u00f6tr hale gelmeyi hedefliyoruz.\u201d<\/p>\n\n\n\n


\u0130klim ve insan sa\u011fl\u0131\u011f\u0131n\u0131n kesi\u015fimine dikkat \u00e7eken Hegemann, \u015funlar\u0131 ekledi: \u201cNet s\u0131f\u0131r olmaya ve karbon n\u00f6trl\u00fc\u011f\u00fcne odaklanan azaltmaya y\u00f6nelik \u00e7abalar \u00f6nemli olsa da, iklim de\u011fi\u015fikli\u011finin k\u00fcresel sa\u011fl\u0131k \u00fczerindeki devam eden etkisini de uyarlamal\u0131 ve y\u00f6netmeliyiz. S\u0131tma gibi hastal\u0131klar\u0131n iklim de\u011fi\u015fikli\u011fiyle \u015fiddetlendi\u011fi bu iklim ve insan sa\u011fl\u0131\u011f\u0131n\u0131n kesi\u015fti\u011fi noktada, do\u011frudan iklimle ilgili tehditleri hedefleyen Ar-Ge yat\u0131r\u0131mlar\u0131na devam etmeli ve sa\u011fl\u0131k alan\u0131nda yenilik\u00e7i \u00e7al\u0131\u015fmalardan olu\u015fan faydalar\u0131n\u0131n herkese ula\u015fmas\u0131n\u0131 sa\u011flamal\u0131y\u0131z.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Novartis Kurtk\u00f6y \u00dcretim Tesisi 2004 y\u0131l\u0131ndan bu yana faaliyet g\u00f6steriyor. Tesistee kanser, hipertansiyon, kolesterol, s\u0131tma ve a\u011fr\u0131 gibi hastal\u0131klar\u0131n tedavisinde kullan\u0131lan bir\u00e7ok Novartis ilac\u0131n\u0131n kat\u0131 oral formlar\u0131 \u00fcretiliyor. S\u00fcrekli iyile\u015ftirme ve yenilik sa\u011flamak i\u00e7in her y\u0131l \u00f6nemli oranda yat\u0131r\u0131m yapan Novartis Kurtk\u00f6y \u00dcretim Tesisi hem T\u00fcrkiye ekonomisine hem de toplum sa\u011fl\u0131\u011f\u0131na katk\u0131da bulunuyor. Tesisin 20. y\u0131l kutlamas\u0131 \u00e7er\u00e7evesinde d\u00fczenlenen etkinlikte Novartis T\u00fcrkiye \u00dclke Ba\u015fkan\u0131 Natacha Theytaz Novartis’in T\u00fcrkiye’deki yat\u0131r\u0131mlar\u0131 ve hedeflerine y\u00f6nelik payla\u015f\u0131mlarda bulundu<\/p>\n","protected":false},"author":1,"featured_media":3551,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3,1],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3547"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3547"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3547\/revisions"}],"predecessor-version":[{"id":3549,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3547\/revisions\/3549"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3551"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}